Regenerative Medical Group provides a remedy for Wound Healing and Erectile Dysfunction (ED) by using non-invasive technology. It partners with clinics to render the service such as reception, treatment rooms and nurses. In addition to the Erectile Dysfunction (ED) market, it has identified wound healing as a new market. Currently, it is working with an experienced NHS/NICE validation team to show its value as a treatment modality. RMG reached revenues of £400k, -56k EBITDA in the financial year 2017, and is operational in 5 clinics.
days to go:
Expired
investment:
£67,740
Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.
days to go:
Expired
investment:
£134,892
Care Oncology Clinic is changing the face of cancer treatment by developing combinations of medicines to be taken alongside existing treatments such as radiotherapy, chemotherapy, hormone therapy and immunotherapy.
days to go:
Expired
investment:
£145,038
Speeding up access to mental health treatments by using electronic forms and universal communication tools. Thalamos has created a solution for multiple health entities such as the NHS, social services, charities, etc. The company aims to move these entities away from pen and paper, to an easy-to-use online platform, as manual entries are prone to information and data being misplaced, as well as prone to errors.
Thalamos's cloud platform will enable psychiatrists to reduce their clinical and information governance risk, whilst helping to continuously improve their patients' recovery process. The product will be subscription-based from £600 per year, which can be paid monthly and is in-line with other professional services.
days to go:
Expired
investment:
£171,548
An innovation event that displays the greatest in medical healthcare technologies within exhibitions, conferences and workshops. GIANT Health has over 2000 delegates registered, with 235 speakers and 33 exhibitors whilst being sponsored by 8 global companies. Current revenue streams consist of event ticket sales, partnership packages, stage demos, etc. Events are held across Europe, with international expansion in the next phase.
days to go:
Expired
investment:
£62,770
BiVictriX Therapeutics is a pharmaceutical company that are developing ADC's (Antibody Drug Conjugates) in the field of Oncology. They have invented a strategy that improves ADC selectivity towards cancer cells.
days to go:
Expired
investment:
£451,506
SuperCarers is an online platform that helps families to find trusted carers living in their local area. SuperCarers do not have the high overhead costs of agencies and therefore enable supercarers to be paid significantly more than the national living wage.
days to go:
Expired
investment:
£1,079,495
Rightangled are a CQC registered healthcare provider specialising in genetic testing and is backed by the NHS England. They have designed and filed a patent for their Cardiac genetic test and are now seeking to expand their testing and telemedicine service into new markets and new tests.
days to go:
Expired
investment:
£433,290
Quin is a mobile medical app that combines daily life experience with data from diabetes devices and phones and helps people decide how much insulin to take and when. They are on a mission to help people with insulin-treated diabetes make the best possible decisions through their app. The company have received a UK research and innovation grant. Apple has granted them insider access to their engineers and executives who are helping to get Quin to market, their app has a class I CE Mark, with two patents pending. With the investment, they will hire a product designer to enhance the user experience, achieve certification and compliance with new European Medical Device Regulations, develope B2B2C distribution partnerships and launch the Quin app in the UK and Europe in late 2020.
days to go:
Expired
investment:
£691,497
Accunea is the world’s first real-time continuous organ function monitoring company, specializing in biomarkers for kidney transplantation. Targeting NHS hospitals in the UK undertaking renal transplantation, the company aims to provide relief to patients awaiting organ transplants by ensuring availability of more organs for transplant and reducing the numbers of deaths due to increasing waiting list times. For this purpose, the company has designed a miniature analysis device which constantly monitors markers of kidney function and metabolism through a standard dribble line put into the vein of a patient. Accunea is raising £400,000 at a pre-money valuation of £2,230,000. The funds will be used to achieve clinical utility in Kidney and Pancreas.
days to go:
Expired
investment:
£388,038
